Protalix BioTherapeutics (PLX) Tops Q2 EPS by 7c

Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.13), $0.07 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $10.97 million versus the consensus estimate of $10.87 million.

"This quarter, we delivered on two very important milestones for the company: announcing positive topline results in our BRIDGE phase III clinical trial of PRX–102 for the treatment of Fabry disease and subsequent BLA submission to the U.S. Food and Drug Administration (FDA). We were able to accomplish these goals even as we faced the challenging headwinds from the global COVID-19 pandemic, and I am very proud of our entire team for their commitment and dedication," said Dror Bashan, Protalix's President and Chief Executive Officer. "As we look towards an exciting second half of the year, we are continuing to build Protalix for the long term. We augmented our research and development team with highly qualified and seasoned veterans to support and enhance our pipeline, and we announced a new partnership to explore the development of PRX–110." Mr. Bashan concluded, "We are gratified to have a balance sheet supporting our strategic plans and look forward to continuing to execute as we move towards the anticipated commercial launch of PRX–102 for the treatment of Fabry disease."

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Bank First National Corp. (BFC) appoints three new directors to board
• Cushman & Wakefield names two capital markets leaders in APAC